DelBello, M. Efficacy and safety of intranasal esketamine for the rapid reduction of depressive symptoms in adolescents with MDD at imminent risk for suicide: results of a double-blind, randomized, psychoactive controlled study. Presented at the annual meeting of the American Academy of Child & Adolescent Psychiatry. October 25, 2023.CrossRefGoogle Scholar

Dwyer, JB, Stringaris, A, Brent, DA, Bloch, MH. Annual research review: defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 2020;61(3):312–32.CrossRefGoogle ScholarPubMed

Dwyer, JB, Landeros-Weisenberger, A, Johnson, JA et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry 2021;178(4):352–62.CrossRefGoogle ScholarPubMed

Fu, DJ, Ionescu, DF, Li, X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind randomized study (ASPIRE I). J Clin Psychiatry 2020;81(3):19m13191.CrossRefGoogle ScholarPubMed

Ionescu, DF, Fu, DJ, Qiu, X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicidal ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol 2021;24(1):22–31.CrossRefGoogle ScholarPubMed

Lineham, A, Avila-Quintero, VJ, Bloch, MH, Dwyer, J. The relationship between acute dissociative effects induced by ketamine and treatment response in adolescent patients with treatment-resistant depression. J Child Adolesc Psychopharmacol 2023;33(1):20–6.CrossRefGoogle ScholarPubMed

Zhou, Y, Lan, X, Wang, C et al. Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2023;S0890-8567(23):00373–8.Google Scholar